RecruitingNot ApplicableNCT06388096

CLAD Deconvolved PERG Responses in Glaucoma Patients


Sponsor

Jorvec Corp.

Enrollment

120 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease is critical so patients may obtain treatment to preserve useful vision. This study will collect data from a population of glaucoma suspects (with positive factors for the disease but with normal vision) along with a population of age matched controls using the pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) which come together to form the optic nerve. RGCs may become dysfunctional before dying. The Continuous loop deconvolution technique (CLAD) will be used to extract transient PERG responses in both glaucoma suspects and age matched controls. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests over 2 years. CLAD will be compared with conventional techniques of monitoring glaucoma (standard PERG, OCT, visual field etc) to see if the CLAD is better at distinguishing between glaucoma suspects and controls.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new type of eye test called a deconvolved pattern electroretinogram (PERG) to detect early signs of glaucoma — a condition where the nerve at the back of the eye is slowly damaged, often before vision loss is noticed. The goal is earlier, more accurate detection. **You may be eligible if...** - You are between 18 and 85 years old - You have characteristics that suggest possible early glaucoma (e.g., large or asymmetric optic disc cup, elevated eye pressure, or a family history of glaucoma-related vision loss) - Your vision with glasses is at least 20/30 - Your eye pressure has been at least 15 mmHg without treatment **You may NOT be eligible if...** - You have age-related macular degeneration, diabetes, Parkinson's disease, or multiple sclerosis - You are pregnant or nursing - You are on prescription eye pressure-lowering drops and unwilling to stop them - Your eye scan already shows clear signs of glaucoma damage Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPattern Electroretinogram

Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.


Locations(1)

University of Miami, Bascom Palmer Eye Institute 900 NW 17th Street

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06388096


Related Trials